

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting***  
Marriott Inn and Conference Center  
University of Maryland University College (UMUC), Adelphi, MD  
December 12, 2011

---

**Meeting Roster**

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Philip A. Bautista, Pharm.D.**

Division of Advisory Committee & Consultant Management (DACCM)  
Office of Executive Programs (OEP), CDER, FDA

**PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Matthew J. Byerly, M.D.**

Associate Professor  
Department of Psychiatry  
The University of Texas Southwestern  
Medical Center at Dallas  
Dallas, TX

**Victor De Gruttola, Sc.D.**

Professor and Chair of Biostatistics  
Department of Biostatistics  
Harvard School of Public Health  
Boston, MA

**Christopher J. Kratochvil, M.D.**

Assistant Vice Chancellor for Clinical Research  
Chief Medical Officer, UNeHealth  
University of Nebraska Medical Center  
Omaha, NE

**Joan L. Luby, M.D.**

Professor of Psychiatry  
Early Emotional Development Program  
Department of Psychiatry  
Washington University School of Medicine  
St. Louis, MO

**Elizabeth McCarthy, M.A.**

*(Consumer Representative)*  
Madison Heights, MI

**Murray B. Stein M.D., M.P.H.**

Professor of Psychiatry and Family & Preventive Medicine  
University of California San Diego  
San Diego, CA

**TEMPORARY MEMBERS (Voting)**

**Mark L. Brantly, M.D.**

Chief and Professor of Medicine  
Division of Pulmonary, Critical Care and Sleep  
Medicine  
University of Florida College of Medicine  
Gainesville, FL

**Dan Budnitz, M.D., M.P.H., CAPT, USPHS**

Director, Medication Safety Program  
Division of Healthcare Quality Promotion  
Center for Disease Control and Prevention  
Atlanta, GA

**Paula Carvalho, M.D.**

Professor of Medicine, Division of Pulmonary and  
Critical Care Medicine, University of Washington  
Section Head, Pulmonary and Critical Care Medicine  
Boise Veterans Affairs (VA) Medical Center  
Boise, ID

**Michael Cohen, R.Ph., M.S., Sc.D.**

President  
Institute for Safe Medication Practices  
Horsham, PA

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting***  
Marriott Inn and Conference Center  
University of Maryland University College (UMUC), Adelphi, MD  
December 12, 2011

---

**Meeting Roster (*continued*)**

**TEMPORARY MEMBERS (Voting)**

**William Greene, Pharm.D.**

Chief Pharmaceutical Officer  
Pharmaceutical Sciences Administration  
St. Jude Children's Research Hospital  
Memphis, TN

**Jerry Krishnan, M.D., Ph.D.**

Professor of Medicine and Public Health  
Section of Pulmonary, Critical Care, Sleep and Allergy  
University of Illinois at Chicago – College of Medicine  
Chicago, IL

**Elaine Morrato, Dr.P.H., M.P.H., C.P.H.**

Associate Professor  
Department of Health Systems, Management and  
Policy, Colorado School of Public Health  
University of Colorado - Denver  
Aurora, CO

**Kenneth E. Towbin, M.D.**

Chief, Clinical Child & Adolescent Psychiatry  
Emotion and Development Branch  
National Institute of Mental Health (NIMH)  
National Institutes of Health (NIH)  
Bethesda, MD

**David Jacoby, M.D.**

Chief, Pulmonary and Critical Care Medicine  
Edwards Professor of Pulmonary Medicine  
Oregon Health and Science University  
Portland, OR

**Margy Lawrence (Patient Representative)**

Potomac, MD

**Peter Terry, M.D.**

Professor of Medicine  
Division of Pulmonary and Critical Care Medicine  
Johns Hopkins Medical Institutions  
Baltimore, MD

**Andrew Winokur, M.D., Ph.D. (Acting Chair)**

Director of Psychopharmacology  
Department of Psychiatry  
University of Connecticut Health Center  
Farmington, CT

**ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)**

**William Z. Potter, M.D., Ph.D.**

*(Acting Industry Representative)*  
Philadelphia, PA

**FDA PARTICIPANTS (Non-Voting)**

**Ellis Unger, M.D.**

Deputy Director, Office of Drug Evaluation I (ODEI)  
Office of New Drugs (OND), CDER, FDA

**Mitchell Mathis, M.D.**

Deputy Director, DPP  
ODEI, OND, CDER, FDA

**Thomas Laughren, M.D.**

Director, Division of Psychiatry Products (DPP)  
ODEI, OND, CDER, FDA

**Theresa Michele, M.D.**

Clinical Team Leader, Division of Pulmonary, Allergy  
and Rheumatology Products (DPARP)  
Office of Drug Evaluation II (ODEII), OND, CDER, FDA